Purposeful PrEP: New insights on lenacapavir for prevention

Thank you for your interest in the IAS oral abstract session Purposeful PrEP: New insights on lenacapavir for prevention, 17 July 2025. The presentations and graphical summaries for selected sessions can be found below:

1. Estimation of the counterfactual HIV incidence in the PURPOSE trials – Colleen Kelley
   • Presentation
2. Efficacy, safety, and pharmacokinetics of twice-yearly subcutaneous lenacapavir for PrEP among adolescents and young people in the phase 3 trials PURPOSE 1 and PURPOSE 2 – Katherine Gill
   • Presentation
   • Graphical summary
3. Preference for twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2 – Kathryn Mngadi
   • Presentation
4. Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics – Linda-Gail Bekker
   • Presentation
   • Graphical summary
5. Lenacapavir dosing in special situations: Tuberculosis and beyond – Linda-Gail Bekker
   • Presentation

Additional data from the PURPOSE 1 and 2 trials at IAS

• TUPEC057: Predictors of HIV Pre-Exposure Prophylaxis Preferences Using the Health Belief Model: Twice-Yearly Subcutaneous Lenacapavir Versus Daily Pills in the PURPOSE 1 Trial
• Leila E Mansoor, Limakatso Lebina , Philisiwe Makhoba , Logashvari Naidoo , Gonasagrie Nair , Dylan Mezzio , Gary Leung , Xin Li , Alexander Kintu , Moupali Das , Quarraisha Abdool Karim
• WEPED077: Factors Impacting Women’s Choice of PrEP Product After the Randomized Blinded Phase of PURPOSE 1
• Thesla Palanee-Phillips, Imogen Hawley, Jennifer Smit, Nzwakie Mosery, Abigail Kubeka, Disebo Potloane, Makhosazane Mdlada, Heeran Makkan, Katherine Gill, Lucia Jola, Zikhona Njengele-Tetyana, Phumla Sibiya, Tara McClure, Christoph C Carter, Alexander Kintu, Moupali Das, and Elizabeth T Montgomery
• EP0725: Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1 
• Alinda M Nyamaizi, Imogen Hawley, Lebogang Isidoro, Heeran Makkan, Buyisiwe L Dlamini, Cecilia Milford, Katherine Gill , Thandeka Nkosi, Nzwakie Mosery, Jennifer Smit, Krishnaveni Reddy, Phumla Sibiya, Tara McClure, Christoph Carter , Alexander Kintu, Moupali Das, Elizabeth T Montgomery

ACCESS: Please see the full access statement here.

Gilead believes working directly with generic manufacturers (voluntary licensing) is the fastest way to create broad and sustainable access to lenacapavir for PrEP for people who need it the most.